QuantiNova’s Post

🚀 Dive into the Future of Clinical Trials with Dr. Daniel Gehrlach, Associate Director for Biomarkers from HMNC Brain Health! 🌟 🧠 HMNC Brain Health is a Munich startup that is about to pioneer the area of precision medicine, specifically #PrecisionPsychiatry. 💡 Daniel sheds light on the complexities and innovations in clinical trials. From genetic selection tools to the challenges of regulatory compliance, he discusses how new technologies like decentralized trials and AI can revolutionize the field. To help you navigate to the sections that interest you the most, use this guidance: 📌 0:15 Introduction 📌 1:36 Regulation of Clinical Trials 📌 4:04 Speech Analysis 📌 5:17 Decentralized Trials 📌 7:39 Time to Market 📌 8:34 Why "being brave" matters 📌 9:10 The right CRO 🧬 For more on technology trends and how they can enhance efficiency in clinical trials, check out the full video or look at some of my other interviews. 🌍 Let's explore how we can push the boundaries of life sciences together! #LifeSciences #ClinicalTrials #PrecisionMedicine #Innovation #Technology #DecentralizedTrials

🎥 We caught up with PathAI CEO, Andrew Beck, VP of Product Ben Glass, and Sr. Translational Scientist Lara P. Murray, PhD to hear their perspective on the impact of our recent #NatureMedicine publication entitled “𝗔𝗜-𝗯𝗮𝘀𝗲𝗱 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗲𝗻𝗿𝗼𝗹𝗹𝗺𝗲𝗻𝘁 𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮 𝗮𝗻𝗱 𝗲𝗻𝗱𝗽𝗼𝗶𝗻𝘁 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗶𝗻 𝗹𝗶𝘃𝗲𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀” which details the development of our solution, AIM-MASH™. Hear more about the details behind developing AIM-MASH™ and using AI-powered #pathology to solve pressing problems in #healthtech, #translationalresearch, clinical trial #enrollment, and more. 📝 You can read the original article here: https://lnkd.in/gaiqqeUx Successful clinical trials in metabolic dysfunction-associated steatohepatitis (#MASH) rely on consistent histologic scoring, which has historically been variable. The developed AI-based measurement tool (AIM-MASH™) demonstrated reproducibility and alignment with expert pathologists, and has the potential to reduce inter-rater variability in MASH clinical trials. AIM-MASH additionally produces continuous scores for each of the MASH CRN (#ClinicalResearchNetwork) components to enable granular measurement of histologic changes. Read more about AIM-MASH, #pathology, and more in our latest paper and by visiting our website: https://lnkd.in/e5c4W8Xc AIM-MASH™ is for research use only. Not for use in diagnostic procedures. #Pathology #biotechnology #biotech #healthcare #machinelearning #MASH #LiverDisease #AI #clinicaltrials

GE HealthCare recently received 𝗙𝗗𝗔 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 for its new Centiloid scaling tool, integrated into the MIMneuro software, to enhance Alzheimer’s disease imaging. This tool quantifies amyloid plaque density in the brain using PET scans, providing a standardized and automated metric that 𝗮𝗶𝗱𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻𝘀 𝗶𝗻 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝗻𝗴 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 with greater confidence. 𝗔𝗺𝘆𝗹𝗼𝗶𝗱 𝗽𝗹𝗮𝗾𝘂𝗲𝘀 are a 𝗸𝗲𝘆 𝗺𝗮𝗿𝗸𝗲𝗿 𝗼𝗳 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 disease, and the Centiloid scale standardizes their measurement, making results comparable across various imaging centers. This development is particularly timely as new amyloid-targeting therapies enter the market, further increasing the need for precise diagnostic tools. With this technology, clinicians can now better determine which patients may benefit from these treatments. At Medidedalia, we recognize the importance of advancing diagnostic accuracy in neurodegenerative diseases. Tools like GE HealthCare’s MIMneuro software align with our mission to enhance personalized care, ultimately improving patient outcomes through early detection and tailored treatments. You can read the full article here: https://lnkd.in/dTJXyZCs #HealthcareInnovation #AIinHealthcare #MedTech #AlzheimersCare #BrainHealth #ImagingTechnology #AI #FDAApproval #NeurodegenerativeDiseases #PETImaging #AmyloidPlaque #DigitalHealth #PrecisionMedicine #PatientCare #MedicalAI #HealthcareTech #MolecularImaging #AIforGood #HealthcareTransformation

🚨🚨🚨 #IntestinalUltrasound has emerged as a: 🌟non invasive 🌟real time 🌟radiation free alternative to biomarkers, radiographic imaging & endoscopy for #precise assessment of the disease activity in patients with #InflammatoryBowelDisease, with special value in: 🌟Children 🌟Elderly 🌟Pregnant patients 🌟Postoperative patients 🌟Multiple co-morbidities We are very excited to partner with Digital to further develop Satisfai Health’s #Sonai (#AI powered Intestinal Ultrasound software), to drive the safe adoption, standardization & proficiency in IUS across the 🌎 #IUS #ArtificialIntelligence #IBD Michael Byrne Solveig Johannessen

NEW COLLABORATION📣: 𝗔𝗜-𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗨𝗹𝘁𝗿𝗮𝘀𝗼𝘂𝗻𝗱 𝗳𝗼𝗿 𝗚𝗮𝘀𝘁𝗿𝗼𝗶𝗻𝘁𝗲𝘀𝘁𝗶𝗻𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 Inflammatory Bowel Disease (IBD) is a debilitating condition characterized by chronic inflammation of the gastrointestinal tract, leading to severe symptoms that significantly affect the patients’ quality of life. It impacts over 320,000 Canadians. Intestinal ultrasound (IUS) is a promising new technique that can be used to monitor and treat IBD patients, which replaces invasive and expensive colonoscopies and other radiological imaging. This project will seek to accelerate the development and initial commercialization of Satisfai Health’s Sonai, a software that uses Artificial Intelligence to conduct automated measurements of IUS images resulting in faster IUS adoption and greater standardization of key measurements. Learn more about the collaboration here: https://bit.ly/4gRqxLq Satisfai Health | Alimentiv | Canadian Bowel Ultrasound Society (CANBUS) | The University of British Columbia | University of Calgary

🎙 A detailed understanding of cell behavior is vital, especially within hepatocytes. We also discuss how cutting-edge technologies like SPAchip by ARRAYS FOR CELL NANODEVICES, SL - A4CELL, are transforming healthcare through advanced cellular analysis. 🔍 Exploring Cellular Storytelling: Understanding disorders begins withunraveling each cell's narrative.. This microscopic storytelling is crucial for several reasons: - Early Detection for Proactive Measures: 🔬 Analyzing cell behaviorallows earlyy detection of abnormalities. This earliesty insight empowers healthcare professionals to take proactive measures, potentially preventing the progression of diseases before symptoms manifest. -Understanding the Complexities of Disorders: 🔬 Knowing intricate cell interactions is essential forunraveling disorders.. By decoding cellular narratives, researchers can gain deeper insights intodiseases' root causes,, paving the way for innovative treatment approaches. 🔥 Living single-cell analysis, facilitated by technologies like SPAchip, is revolutionizing cellular language decoding.. Here's why SPAchip is a game-changer: - Precision at the Single-Cell Level: 🧪 SPAchip technology allows researchers to analyze individual cells, providing unprecedented precision in understanding cellular behavior. - Interdisciplinary Collaboration: 🧪 Collaborating across disciplines is key to fullyrealizing single-cell analysis potential.. SPAchip technology encourages interdisciplinary approaches, fostering collaboration among scientists, biologists, and medical professionals. 🚀 Transforming healthcare: Decoding cellular narratives is at the heart of healthcare innovation, and ARRAYS FOR CELL NANODEVICES, SL - A4CELL is on the front lines. Our goal is to transform healthcare with SPAchip technology. 👉 Please ask us about that at SLAS (Society for Laboratory Automation and Screening) Congress next week in Boston, we would be happy to resolve all your questions. 🔬 #SPAchip #CellBiology #HealthcareInnovation #PersonalizedMedicine #ScienceCommunication #CellularAnalysis #MedicalResearch 🧪

🗓Are you ready for #AFSymposium 2024 in Boston?   ➡Dr. Jose Osorio will be providing an update on Volta Medical's clinical evidence roadmap during Spotlight Session I. Join us on Day 1 from 8:30-9:30 AM to learn about our clinical evidence roadmap. #EPeeps #AI #EP #electrophysiology 

We're pleased to introduce our novel Causal Responders Detection (CARD) method, detailed in our latest publication. CARD applies machine learning and causal tree techniques to identify individuals who benefit significantly from treatments, ensuring false discovery control in both RCTs and observational studies. This method refines our understanding of individual treatment responses, providing crucial insights for precision medicine development. Our simulations confirm CARD's effectiveness across various settings, enabling to apply this method across therapeutic areas and clinical phases. #PersonalizedMedicine #MachineLearning #ClinicalTrials #HealthcareInnovation Tzviel Frostig Oshri Machluf Elad Berkman Raviv Pryluk Amitay Kamber

𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞: 𝐇𝐨𝐰 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐢𝐬 𝐂𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐓𝐡𝐞 𝐆𝐚𝐦𝐞 The personalized medicine market size was valued at USD 538.93 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.20% from 2023 to 2030. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 @ https://lnkd.in/gBNgZF4Y #Precision_medicine, also known as personalized medicine, is an approach to medical care and treatment that takes into account individual variability in genes, environment, and lifestyle for each person. The goal of precision medicine is to tailor #medical decisions, interventions, and treatments to the specific characteristics of each patient, rather than adopting a one-size-fits-all approach. Traditional medicine often relies on general guidelines and population-based treatments, which might not be effective for every individual due to differences in genetics, metabolism, and other factors. #Precisionmedicine aims to address this limitation by considering a person's unique genetic makeup, #molecular profiles, and other personal information to provide more accurate #diagnoses, #treatment plans, and disease prevention strategies. 𝑭𝒐𝒓 𝑴𝒐𝒓𝒆 𝑰𝒏𝒇𝒐𝒓𝒎𝒂𝒕𝒊𝒐𝒏 @ https://lnkd.in/gR8Pu7ag ✅ Genomics: This involves studying an individual's genetic information, such as #DNA sequences, to identify genetic variations that might contribute to diseases or affect how an individual responds to specific treatments. ✅ Molecular Profiling: Precision #medicine also involves analyzing various molecules in the body, such as #proteins, metabolites, and #RNA, to understand disease mechanisms and tailor treatments accordingly. ✅ Data Integration: Precision medicine relies on a comprehensive approach that incorporates various types of data, including #clinical, #genetic, environmental, and lifestyle information, to create a more holistic picture of an individual's #health. 𝐓𝐨𝐩 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐚𝐫𝐞 The Ohio State University Wexner Medical Center | Vanderbilt University Medical Center | Myriad Genetics | Caris Life Sciences | Verily | Penn State Health | Worldwide Clinical Trials | Oakland University | Metagenics | Carbon Health | Ivy Rehab Physical Therapy | Yale New Haven Health | OrthoCarolina | Horace Mann | Genomic Health | +MEDRITE Urgent Care | GENETWORx | LightForce | RAYUS Radiology

𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗨𝗿𝗶𝗻𝗲 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟬. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dw9w4dth The report offers a comprehensive overview of the Clinical Urine Testing industry, encompassing the development of its supply chain, market status in disease screening and physical condition diagnosis through methods like urine test strips and microscopic examination, and key players in both established and emerging markets. It delves into cutting-edge technologies, patents, applications, and market trends, with a focus on regions such as North America, Europe, and Asia-Pacific, particularly China, which leads in global Clinical Urine Testing due to strong domestic demand, favorable policies, and robust manufacturing. The analysis provides a thorough understanding of market dynamics, trends, challenges, and opportunities, offering a holistic view of the industry and detailed insights into its various components and stakeholders. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗨𝗿𝗶𝗻𝗲 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dw9w4dth *𝗕𝘆 𝗧𝘆𝗽𝗲: Urine Test Strip, Microscopic Examination, Others *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Disease Screening, Physical Condition Diagnosis, Health Monitoring *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Mayo Clinic, Cleveland Clinic, Harbor-UCLA Medical Center, Johns Hopkins Hospital, Massachusetts General Hospital, Cedars-Sinai, NewYork-Presbyterian Hospital, NYU Langone Health, Northwestern Memorial Hospital, Michigan Medicine, Brigham and Women's Hospital, Houston Methodist, Barnes-Jewish Hospital, Mount Sinai Hospital (Toronto), Sinai Health, RUSH University Medical Center, Vanderbilt University, Siemens Healthineers, Roche, Beckman Coulter Diagnostics, Sysmex Corporation, 77 Elektronika Ltd., Analyticon Biotechnologies GmbH, Erba Mannheim, ACON Laboratories #UrineTest #MedicalTesting #HealthcareTechnology #DiagnosticTests #Urinalysis #DiseaseScreening #HealthAwareness #PublicHealth #MedicalInnovation #HealthTech #LabTesting #Urology #WellnessCheck #PatientCare #PrecisionMedicine